29339900

Benign prostatic hyperplasia (referred as BPH) is one of the most common diseases in older male with the non-malignant prostate being the character.
It can cause the obstructive urination symptoms and other irritation symptoms which have brought significant negative impact on the life of older people.
In recent years, with the increasing level of industrialization of China, the annual intake of animal protein intake gradually increased and life expectancy increases, the incidence of benign prostatic hyperplasia also has increased year by year.
Over 50 percent in elderly people at age 60 or above has got this disease.
This ratio increases to over 90% for elderly people over 85 years-old. Its triggering factor has not been totally elucidated.
It is generally believed that this is related to the secretion of sex hormones and cholesterol as well as other kinds of metabolic disorders.
Some people think that, for elder people, their weakened pituitary-gonadotropin-pathway or endogenous change cause degeneration of testicles decreased sexual function, reduced testosterone value, as well as the change of glandular epithelium and enlarged prostate caused by the increased connected tissue of prostate.
The enlargement of prostate will compress the urethra, resulting in poor urine flow of bladder and even blocked bladder outlet.
There is α1A-adrenergic receptor located in the human prostate.
The activation of the receptor will deteriorate the symptoms of dysuria and urethral obstruction.
Therefore, by blocking the binding α1A-adrenergic receptor, we can relax the obstructed prostate smooth muscle relaxation, and thereby alleviating the symptoms.
In recent years, people has achieved excellent efficacy by clinically applying 5α-reductase inhibitors and α1-adrenergic receptors (α1-AR) blocker (silodosin).
This is considered as a major breakthrough in drug treatment of benign prostatic hyperplasia.